Hidradenitis Suppurativa Clinical Trial
Official title:
A Bioelectric Dressing for Post De-Roofing Treatment of Hidradenitis Suppurativa (HS)
Verified date | February 2024 |
Source | University of Miami |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this study is to test if the use of a bioelectric dressing can improve healing after a surgical procedure called de-roofing.
Status | Active, not recruiting |
Enrollment | 12 |
Est. completion date | August 1, 2024 |
Est. primary completion date | August 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adults 18 years old and older. - Have diagnosis of HS confirmed by a dermatologist - Have at least two ancillary tunnels in separate anatomical sites - Able to provide informed consent Exclusion Criteria: - Individuals who are not yet adults - Subject is allergic to any of the materials and dressings involved in the procedures - Women known to be pregnant - Prisoners - Subjects, who in the opinion of the PI, cannot comply with hope application of the treatment |
Country | Name | City | State |
---|---|---|---|
United States | University of Miami | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Miami | Vomaris Innovations |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Healing Rate | The healing rate of post-surgical wounds will be reported as the area reduction in cm^2/per day. | Up to 8 weeks | |
Secondary | Average time to complete healing | The average time, measured in days, to complete healing as assessed by treating physician will be reported | Up to 8 weeks | |
Secondary | Number of subjects with complete healing | The number of subjects with complete post-surgical site healing, as evaluated by treating physician, will be reported. | Up to 8 weeks | |
Secondary | Number of subjects with nodule and/or tunnel recurrence | The number of subjects with nodule and/or tunnel recurrence, as evaluated by treating physician, will be reported. | Up to 8 weeks | |
Secondary | Average pain as assessed by the Numerical Rating Scale (NRS) | The average pain will be measured using the NRS with scores ranging from 0-10 with the higher score indicating more severe pain. | Up to 8 weeks | |
Secondary | Number of subjects with tenderness at surgical sites | The number of subjects with tenderness at surgical sites, as evaluated by treating physician, will be reported. | Up to 8 weeks | |
Secondary | Quality of post-surgical scars as measured by the Hurley Stage score | The Hurley score is staged as: 1 (single or multiple abscesses without sinus tract formation or scarring); 2 (recurrent abscesses with one or more sinus tracts and scarring widely separated by normal skin); 3 (diffuse involvement with multiple sinus tracts and no intervening normal skin) | Up to 8 weeks | |
Secondary | Amount of exudate at surgical site | The amount of exudate at surgical site will be evaluated using a 5 point Likert scale from 0 (Dry) to 4 (Leaking). | Up to 8 weeks | |
Secondary | Shoulder range of motion | Shoulder range of motion will be measured using a goniometer | Up to 8 weeks | |
Secondary | Number of dressings used through to healing day | The number of dressings used through to healing day will be reported | Up to 8 weeks | |
Secondary | Pain after procedure as assessed by the NRS | The average pain will be measured using the NRS with scores ranging from 0-10 with the higher score indicating more severe pain. | Day 2 (24 hours post procedure) | |
Secondary | Days of work lost | Participants reported days of work lost due to the procedure will be reported | Up to 8 weeks | |
Secondary | Change in Quality of Life as measured by the DLQI | Dermatology Life Quality Index (DLQI) has a total score ranging from 0 to 30 with the lower score indicating higher health related quality of life | Baseline, Up to 8 weeks | |
Secondary | Tissue analysis of microbiome | As measured by quantitative 16s rDNA Polymerase Chain Reaction for bacterial enumeration from punch biopsy and biofilm samples. | Up to 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02904902 -
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
|
Phase 3 | |
Completed |
NCT03628924 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
|
Phase 2 | |
Not yet recruiting |
NCT05531747 -
Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa
|
N/A | |
Recruiting |
NCT06028230 -
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 2 | |
Completed |
NCT03275870 -
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
|
Phase 1/Phase 2 | |
Completed |
NCT03248531 -
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
|
Phase 2 | |
Withdrawn |
NCT04100083 -
Spironolactone for Hidradenitis Suppurativa
|
Phase 4 | |
Completed |
NCT00329823 -
Etanercept in Hidradenitis Suppurativa
|
Phase 2 | |
Recruiting |
NCT05710393 -
Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
|
||
Completed |
NCT04019041 -
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
|
Phase 2 | |
Completed |
NCT05286567 -
A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.
|
Phase 1 | |
Withdrawn |
NCT03929835 -
Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa
|
Phase 2 | |
Terminated |
NCT04325607 -
Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa
|
N/A | |
Terminated |
NCT03238469 -
Microwave Ablation in Mild Axillary Hidradenitis Suppurativa
|
N/A | |
Completed |
NCT04449354 -
HidraWear AX HS Study
|
N/A | |
Recruiting |
NCT06123429 -
Mindfulness in Hidradenitis Suppurativa
|
N/A | |
Recruiting |
NCT05934825 -
Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa
|
Phase 1/Phase 2 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Recruiting |
NCT06046729 -
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 2 | |
Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 |